Nationwide Real-World Exclusive Enteral Nutrition Practice Over Time: Persistence of Use as Induction for Pediatric Crohn’s Disease and Emerging Combination Strategy With Biologics

• Published in: Inflammatory bowel diseases 2024-08, Vol.30 (8), p.1258-1263
• Main Authors: Wands, David I F, Gianolio, Laura, Wilson, David C, Hansen, Richard, Chalmers, Iain, Henderson, Paul, Gerasimidis, Konstantinos, Russell, Richard K
• Format: Article
• Language: English
• Subjects: Adolescent; Biological Products - therapeutic use; Child; COVID-19 - epidemiology; Crohn Disease - therapy; Enteral Nutrition - methods; Enteral Nutrition - statistics & numerical data; Female; Humans; Male; Remission Induction; Retrospective Studies; SARS-CoV-2; Scotland - epidemiology
• ISSN: 1078-0998; 1536-4844; 1536-4844
• DOI: 10.1093/ibd/izad167

Abstract Background Exclusive enteral nutrition (EEN) is the recommended first-line induction treatment in pediatric patients with active luminal Crohn’s disease (CD). We aimed to provide a nationwide overview of evolving EEN practices during an era of increasing biologic use. Methods We analyzed a prospectively identified nationwide cohort of newly diagnosed pediatric patients with CD in Scotland between January 1, 2015, and June 30, 2022. Patients who received EEN for any indication were divided into 6-monthly epochs and examined over time. Differences during the COVID-19 pandemic (March 16, 2020, to July 19, 2021) were examined. Data were retrospectively collected from electronic medical records: demographics, anthropometrics, concomitant treatments, aspects of EEN administration, and remission/response rates. Descriptive statistics and linear regression were used for analyses. Results A total of 649 patients with CD were identified (63% male; median age 12.6 [interquartile range, 10.8-14.8] years); 497 (77%) of 649 received EEN as postdiagnosis induction therapy with a median course length of 7.7 (interquartile range, 5.9-8.0) weeks. Including repeat courses, 547 EEN courses were examined. An increasing incidence of CD was observed over time with no significant changes in EEN usage, remission or response rates, nasogastric tube usage, or course completion (all P > .05). Increasing use of EEN combined with biologics (combination induction) as first-line induction was observed over time (P < .001). Considering COVID-19, lower rates of EEN usage were observed (P = .008) with no differences in remission, oral administration, and course completion rates (all P > .05). Conclusions Over the past 7.5 years, except during the COVID-19 pandemic, EEN usage rates have not changed despite an increase in biologic use, although combination induction is an emerging trend.